Tag Archives: healthcare

Aleris to acquire Proliva from Praktikertjänst

Triton

Stockholm (Sweden) 10 December 2019 – Aleris AB (Aleris), a Triton portfolio company, has signed an agreement to acquire Proliva AB (Proliva), a leading Swedish specialist healthcare provider, from Praktikertjänst AB (Praktikertjänst).

Formed as a consolidated and autonomous group through the combination of twelve specialist care subsidiaries of Praktikertjänst in April 2019, Proliva has a strong market position within segments such as geriatrics and psychiatry amongst a total of 30 specialist areas with more than 2 400 employees.

Aleris, which was acquired by Triton fund V in October 2019, is a provider of specialist healthcare and radiology with a strong footprint across Scandinavia. The company’s specialist healthcare operations cover local hospitals, outpatient clinics and radiology through more than 100 units with approximately 1.1 million patient visits and 1 million radiological examinations annually.

“The acquisition of Proliva strengthens our position within specialist healthcare, more than doubling our footprint on the Swedish market. As a leading specialist healthcare provider, offering a broad range of high-quality services, Aleris will strengthen the position as an attractive, long term partner for the public health care services in Sweden.  With this add-on, Aleris also achieves a scale and critical mass that enables greater leverage from digital investments”, says Thomas Berglund, acting CEO and chairman of the Board of Aleris.

“We are excited to join forces with Aleris and to continue our path of being a force of change in the Swedish healthcare systems. Together with our new group colleagues, we now have the best possible conditions to become Sweden’s most attractive specialist healthcare company for patients, employees and payors through high availability, clinical quality and patient satisfaction”, says Cecilia Halvars Öhrnell, CEO of Proliva.

The acquisition is subject to regulatory approval and terms of the transaction are not disclosed.

About Aleris
Aleris is one of Scandinavia’s leading private healthcare companies. The company conducts healthcare and diagnostics in Sweden, Norway and Denmark. Aleris offers high quality services to the public care system, to insurance companies and to patients who pay for their own health care.

Aleris’ mission is to offer the opportunity of a better and healthier life while helping to increase benefits for society through innovative solutions. High quality services are a prerequisite for our business.

Aleris has sales of SEK 4.4 billion and is owned by Triton.

About Proliva
Proliva is Sweden´s largest speciality care group, with twelve subsidiaries and approximately 2400 employees. The group has been a force for change in the Swedish healthcare system for almost 40 years.

Proliva is today comprised of BB Stockholm, CityAkuten, Närsjukhusen i Västra Götaland, Närsjukvården Österlen, Praktikertjänst Anestesi, Praktikertjänst N.Ä.R.A., Praktikertjänst Psykiatri, Praktikertjänst Ryggkirurgi Strängnäs, Rehab Station Stockholm, Sollentuna specialistklinik, Stockholm Heart Center and Ultragyn.

Proliva is a fully owned subsidiary of Praktikertjänst AB.

About Triton

Since its establishment in 1997, Triton has sponsored nine funds, focusing on businesses in the industrial, business services, consumer and health sectors. The Triton funds invest in and support the positive development of medium-sized businesses headquartered in Europe.

Triton seeks to contribute to the building of better businesses for the longer term. Triton and its executives wish to be agents of positive change towards sustainable operational improvements and growth.

The 42 companies currently in Triton’s portfolio have combined sales of around €16,7 billion and around 80,800 employees.

Press Contacts

Triton
Fredrik Hazén
Phone: +46 709 483 810

Categories: News

Tags:

Sale of Générale Beaulieu Immobilière SA to Infracore SA

Aevis

Fribourg, 9 December 2019

AEVIS VICTORIA SA: Sale of Générale Beaulieu Immobilière SA to Infracore SA

Générale Beaulieu Holding SA (GBH), a subsidiary of AEVIS VICTORIA SA, sold its stake in Générale Beaulieu Immobilière SA (GBI) to Infracore SA. This transaction, based on a property value of CHF 196 million, will be paid in cash and shares, allowing AEVIS VICTORIA to increase its direct and indirect stake in Infracore from 19% to 30%. GBH realises a gain on participation of CHF 153 million and will pay an extraordinary dividend of CHF 75 million to its shareholders. AEVIS VICTORIA, the majority shareholder of GBH (69.4%), will achieve a consolidated profit of CHF 21.7 million on this transaction in 4Q2019 and increase its available cash by more than CHF 80 million.

GBI, a subsidiary of GBH, owns several properties in the Champel district, including the Clinique Générale-Beaulieu. The rental surface of the buildings amount to 19’005m2. GBI is currently building a new underground complex of nearly 1’000m2 to house the radiotherapy facilities of the future Cancer Center of Clinique Générale-Beaulieu. GBI’s real estate assets were valued at CHF 196 million in this transaction.

For further information:
AEVIS VICTORIA SA Media and Investor Relations: c/o Dynamics Group, Zurich
Philippe R. Blangey, prb@dynamicsgroup.ch, +41 (0) 43 268 32 35 or +41 (0) 79 785 46 32
Séverine Van der Schueren, svanderschueren@aevis.com, +41 (0) 79 635 04 10

AEVIS VICTORIA SA – Investing for a better life
AEVIS VICTORIA SA invests in healthcare, hospitality & lifestyle and infrastructure. AEVIS′s main shareholdings are Swiss Medical Network SA, the second largest group of private hospitals in Switzerland, Victoria-Jungfrau AG, a luxury hotel group managing luxury hotels in Switzerland, Infracore SA (19%), a real estate company dedicated to healthcare-related infrastructure, a hospitality real estate division, Medgate (40%), the leading telemedicine provider in Switzerland, and NESCENS SA, a brand dedicated to better aging. AEVIS is listed on the Swiss Reporting Standard of the SIX Swiss Exchange (AEVS.SW). www.aevis.com.

 

End of ad hoc announcement

Categories: News

Tags:

Canopy Biosciences Acquires Core Diagnostics

Canopy’s multi-omic immune profiling platform to become available in Core Diagnostics’ CLIA-certified laboratory

ST. LOUIS, Dec. 4, 2019 /PRNewswire/ — Canopy Biosciences, LLC announced today the acquisition of Core Diagnostics, a leading CLIA-certified provider of biomarker analysis services for biopharmaceutical researchers. With the acquisition of Core Diagnostics, Canopy Biosciences will be able to perform its multi-omic immune profiling services in the highly regulated CLIA environment. In addition to NanoString transcriptional profiling, Core Diagnostics also offers histopathology services including immunohistochemistry (IHC) and fluorescent in situ hybridization (FISH). The acquisition of Core Diagnostics follows the acquisition of Zellkraftwerk, GmbH, which joined Canopy earlier this year. Both acquisitions were made possible by strategic growth investments from Ampersand Capital Partners.

Edward Weinstein, Ph.D., CEO and President of Canopy Biosciences commented, “By combining multi-omic technologies such as Chip Cytometry, NanoString, and RareSeq, we are building a unique and powerful platform for immune profiling of cells and tissues. Through the addition of Core Diagnostics, this innovative multi-omics platform will now be available to customers in the clinical space in addition to the preclinical and translational customers we already work with.”

K. Balachandran, CEO of Core Diagnostics said, “Core Diagnostics is excited to join Canopy Biosciences. Our customers have been asking us to add services to more comprehensively satisfy their outsourcing needs. In Canopy and Ampersand we have found the partners that will allow us to add to our capabilities and better serve our customers.”

Frank Witney, Ph.D., Operating Partner at Ampersand and Chairman of Canopy added, “With the prior addition of Chip Cytometry to Canopy, we were able to add a technology that bolstered Canopy’s multi-omic approach to immune profiling. Now, through the addition of Core Diagnostics, we are able to bring this innovative platform to a CLIA-certified lab to serve customers in the clinical space.”

About Canopy Biosciences

Canopy Biosciences was formed in 2016 and has rapidly built a comprehensive portfolio of products and services for gene editing, gene expression analysis and regulation, and bioprocessing. Canopy’s gene editing portfolio offers easy-to-use CRISPR kits and full service custom cell line engineering. Canopy has assembled an innovative multi-omic platform for immune profiling, including ultrasensitive DNA sequencing (RareSeq), RNAseq, NanoString gene expression analysis, and multiplexed protein detection in cells and tissue samples via Chip Cytometry. Canopy Biosciences is headquartered in St. Louis, Missouri, and serves researchers at universities, research institutions and biotechnology and pharmaceutical companies worldwide. Additional information is available at www.canopybiosciences.com.

About Core Diagnostics

Core Diagnostics is a California licensed CLIA-certified laboratory offering biomarker analysis and translational research support for studies ranging from early discovery to analyses of Phase III clinical trial samples. Core’s research group works with clients to develop biomarker strategies and assays collaboratively by functioning seamlessly as an extension of their team and executing on their requirements. Taking a technology agnostic approach, Core Diagnostics offer services in histopathology, IHC, FISH, mutational analysis and high-throughput gene expression studies. Core’s laboratory has implemented cutting edge platforms for molecular analysis including the nCounter® Analysis System from NanoString®™ HD System from Fluidigm for gene expression studies, the Allegro™ fluorescent imaging system and Solo™ workstation from Bioview for FISH analysis and the intelliPATH IHC platform from Biocare Medical. For more information, please visit www.corediagnostics.net.

About Ampersand Capital Partners

Founded in 1988, Ampersand is a middle market private equity firm dedicated to growth-oriented investments in the healthcare sector. With offices in Boston and Amsterdam, Ampersand leverages its unique blend of private equity and operating experience to build value and drive superior long-term performance alongside its portfolio company management teams. Ampersand has helped build numerous market-leading companies across each of our core healthcare sectors, including Brammer Bio, Avista Pharma, Confluent Medical, Genewiz, Genoptix, Talecris Biotherapeutics and Viracor-IBT Laboratories. Additional information is available at ampersandcapital.com.

SOURCE Canopy Biosciences

Related Links

http://www.canopybiosciences.com

Categories: News

Tags:

Imcheck Therapeutics raises USD 53 million, Gimv increases its investment in the immuno-oncology space

GIMV

04/12/2019 – 06:45 | Portfolio

In a Series B financing round of USD 53 million, Gimv is increasing its investment in French ImCheck Therapeutics (www.imchecktherapeutics.com), an emerging player in the field of cancer and auto-immune immunotherapies. The round was co-led by Pfizer Ventures (NYSE: PFE) and Bpifrance and joined by new investors specialized in life sciences. Gimv and other existing shareholders also participated for a significant portion of this raise.

The proceeds of the Series B will be used to fund the initial clinical trial for ImCheck’s first-in-class monoclonal antibody ICT01, to further expand the company’s broad pipeline of immunomodulators targeting the butyrophilins super-family and to bring additional immuno-oncology antibody programs into the clinic.

Bram Vanparys, Partner in Gimv’s Health & Care platform, about this new phase: “Imcheck has made significant progress since our investment in its Series A. We are very proud to have complemented Imcheck’s existing investors syndicate with a mix of reputable US and EU investors. Gimv’s significant participation in this Series B shows our firm belief in the impact Imcheck’s pipeline can have in the oncology and autoimmune space.”

Categories: News

Tags:

Lumeon partners with Medtronic on value-based care

GIlde Healthcare

Utrecht (the Netherlands) and London, (UK) – Lumeon, the leader in Care Pathway Management (CPM), today announced that it has entered a strategic partnership with Medtronic, a global leader in medical technology, services, and solutions, that will support Medtronic’s European healthcare provider customers in their transition to efficient, value-based care models.

Through the partnership, Medtronic’s Integrated Healthcare Solutions (IHS) business will leverage Lumeon’s leading CPM Platform to operationalise care pathways for surgery optimization and chronic disease management. These pathways allow providers to create more effective care coordination that reduces the cost of care delivery while minimising unwarranted variation in care.

Medtronic IHS aims to enhance the efficiency and effectiveness of patient care settings, such as cardiac catheterisation labs and operating rooms, while optimising patient pathways and care delivery from the time a patient is referred for treatment to the time he or she has fully recovered.

“As the global healthcare market undergoes a transition from activity-based reimbursement to outcome-based reimbursement, providers are faced with the challenge of reinventing their business models while delivering care that ensures high-quality clinical, operational, and financial outcomes,” said Robbie Hughes, founder and CEO at Lumeon. “We are proud to be working with Medtronic, a company with a well-earned reputation in value-based care models, to help providers master that transition.”

“We are partnering with over 100 hospitals in Europe to develop evidence-based, best practice-informed pathways that deliver superior outcomes for the lowest possible cost,” said Frederic Noël, vice president, Medtronic IHS EMEA. “To help our customers embed these pathways in daily practice and apply them at scale, across their patient groups, we need more than pathway reference models and change management services. We must provide them with solutions to digitalise the pathway, and automate and orchestrate multi-disciplinary care delivery, leveraging Lumeon’s CPM platform.”

Lumeon’s CPM platform ensures that every patient stays on a personalised plan of care throughout his or her entire healthcare journey. It leverages intelligent automation and orchestration to manage a shared plan of care across multiple teams and settings, automatically adjusting activities and deploying the right resource required for each individual patient in real-time.

 

About Lumeon
Lumeon provides Care Pathway Management (CPM) solutions for healthcare organizations. Its industry-leading platform combines evidence-based pathways with deep operational expertise to deliver better care at lower cost.
A patient-first approach to pathway design, orchestration and automation ensures healthcare provider resources are optimized to deliver superior outcomes at less cost, achieving the goals of new reimbursement models.
Progressive health systems in the USA and Europe have deployed Lumeon’s multi-award winning platform across more than 2,000 care locations. For more information, visit the company’s website at www.lumeon.com

About Gilde Healthcare
Gilde Healthcare is a specialized European healthcare investor managing € 1 billion ($ 1.2 billion) across two fund strategies: venture & growth capital and private equity. Gilde Healthcare’s venture & growth capital fund invests in health tech and therapeutics. The venture & growth companies are based in Europe and North America. Gilde Healthcare’s private equity fund invests in profitable European lower mid-market healthcare companies with a focus on the Benelux and DACH region. The private equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. For more information, visit the company’s website at www.gildehealthcare.com

Categories: News

Tags:

IK Investment Partners acquires Ondal Medical Systems

ik-investment-partners

IK Investment Partners (“IK”) is pleased to announce that the IK VIII Fund has reached an agreement to acquire Ondal Holding GmbH (“Ondal” or “the Company”), a leading Original Design Manufacturer (“ODM”) of medical pendant systems used mainly in operating rooms and intensive care units, from funds advised by Capvis.

Founded in 1945, Ondal has become the global #1 provider of medical pendant systems. With its innovative and broad product portfolio applied in settings such as operating rooms, intensive care units as well as diagnostic and imaging rooms, Ondal sets the global quality standard for medical pendant systems in terms of reliability, functionality and usability. Products manufactured by Ondal are internationally certified in various regulated markets, ensuring compliance with the highest quality standards. Headquartered in Hünfeld, Ondal operates three strategically located manufacturing sites in Germany, the US and China, employing over 500 people.

“With our high-quality pendant products, we carry, move and supply medical equipment to create optimal working conditions. This has enabled us to establish longstanding relationships with international blue-chip customers. IK is the ideal partner as they have a profound understanding of medical technology end-markets and share our vision for growth. We would like to thank Capvis for its support during our partnership,” said Bernd Fabian, CEO of Ondal.

“Ondal is the globally leading platform for medical pendant systems and trusted strategic partner to medical technology companies. Together with management, we will continue to build on the Company’s strong market position as technology leader in its product segment,” said Anders Petersson, Partner at IK and advisor to the IK VIII Fund.

Ondal represents the IK VIII Fund’s fourth Mid Cap acquisition this year, and the 15th acquisition announced by the Fund. Financial terms of the transaction are not disclosed.

Parties involved:
IK Investment Partners: Anders Petersson, Adrian Tanski, Daniel-Vito Günther
Buyer financial advisor: Quarton (Konstantin Schönborn, Rolf Holtmann)
Buyer strategic due diligence: Alvarez & Marsal (Georg Hochleitner)
Buyer financial due diligence: Eight Advisory (Michael Wahl)
Buyer legal advisor: Renzenbrink & Partner (Ulf Renzenbrink)
Capvis: Eric Trüeb, Leif-Niklas Fanter
Seller financial advisor: William Blair (Philipp Mohr, Eike Dickmann)
Seller legal advisor: Hengeler Müller (Daniel Wiegand)

For further questions, please contact:

IK Investment Partners 
Anders Petersson, Partner
Phone: +49 40 369 8850

Mikaela Murekian, Director Communications & ESG
Phone: +44 77 87 573 566
mikaela.murekian@ikinvest.com

About Ondal Medical Systems
Ondal is one of the world’s leading developer and manufacturer of medical pendant systems that facilitate movement, support loads and supply medical equipment with light, gas or data. For more information, visit www.ondal.de

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 130 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

Categories: News

Tags:

IK Investment Partners to support Mabtech

ik-investment-partners

IK Investment Partners (“IK”) is pleased to announce that the IK Small Cap II Fund has reached an agreement to acquire Mabtech, a leading specialist in immune monitoring. The founders and management team will continue to be invested. Merieux Equity Partners (“MxEP”) will acquire a minority stake alongside the Fund. Financial terms of the transaction are not disclosed.

Founded in Sweden in 1986, Mabtech has gained worldwide recognition for its high quality monoclonal antibodies and technical innovation capabilities and is viewed as a pioneer within the growing detection platform techniques of ELISpot and FluoroSpot. To complement its offering, the Company successfully entered the instruments market by launching its first reader, IRIS, in December 2018. Mabtech’s products are used by researchers and companies worldwide to study immune responses in e.g. cancer, allergy, infectious diseases as well as to monitor vaccine trials.

“Mabtech has become a well-reputable brand worldwide due to their high quality, innovation and excellent customer service, supporting their customers to obtain optimised test results with limited variability. The deal team has followed the company for several years and we understood this was a unique opportunity to acquire a global leader in a niche market and we are delighted to be the founders’ preferred partner for Niklas and his experienced team,” said Erik Ingemarsson, Partner at IK Investment Partners and advisor to the IK Small Cap II Fund.

“We describe Mabtech as a company ‘founded by researchers for researchers’. Our success is built on long-term relationships with our clients and employees, and as we started planning for our next phase of growth, it was clear that we needed a partner who shares our values and vision. We could not be more happy about this exciting new partnership,” said Niklas Ahlborg, CEO of Mabtech.

Benoit Chastaing, Senior Partner at Merieux Equity Partners added: “We are pleased to partner with IK Investment Partners, founders and Mabtech management team, to invest in a reference player in the immunoassays market. This attractive and growing segment has been a core focus for MxEP and we aim at bringing our expertise and industrial network to accompany Mabtech in its development together with IK.”

The investment in Mabtech builds on IK’s strong track record in healthcare, following its successful sale of Ellab, a leading global supplier of thermal validation solutions, to EQT in September 2019, and its acquisition of LAP Laser, a leading German provider of laser positioning systems, in July 2019.

The transaction represents the 8th investment made by the IK Small Cap II Fund, and the team included Erik Ingemarsson, Kristian Carlsson Kemppinen, Henrik Geijer, Viktor Josefsson and Patrik Stockhaus.

Completion of the transaction is expected during December.

For further questions, please contact:

Mabtech
Niklas Ahlborg, CEO
niklas@mabtech.com

IK Investment Partners
Erik Ingemarsson, Partner
Phone: +46 8 678 95 00

Mikaela Murekian, Director Communications & ESG
Phone: +44 77 87 573 566
mikaela.murekian@ikinvest.com

About IK Investment Partners
IK Investment Partners (“IK”) is a Pan-European private equity firm focused on investments in the Nordics, DACH region, France, and Benelux. Since 1989, IK has raised more than €10 billion of capital and invested in over 125 European companies. IK funds support companies with strong underlying potential, partnering with management teams and investors to create robust, well-positioned businesses with excellent long-term prospects. For more information, visit www.ikinvest.com

Categories: News

Tags:

Cinven and Astorg to acquire LGC

Cinven

A consortium jointly led by Astorg and Cinven today announces that it has signed an agreement to acquire LGC, a global leader in the Life Sciences Tools sector.

LGC provides a comprehensive range of measurement tools, proficiency testing schemes, supply chain assurance standards and specialty genomics reagents underpinned by leading analytical and measurement science capabilities. Its scientific tools and solutions form an essential part of its customers’ quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. The company serves customers across a number of end markets, including human healthcare, agri-food and the environment.

Established in 1842, today LGC employs more than 3,200 people, including many internationally-recognised scientific experts in their field. LGC is headquartered in the UK and serves almost 50,000 laboratories worldwide from its global office network spanning 22 countries across five continents.

Astorg and Cinven identified LGC as an attractive investment opportunity given its:

  • Leading positions in the healthcare, food and agriculture markets, underpinned by its long-standing reputation for scientific expertise and high quality products;
  • Strong performance and organic growth aided by investment in people, key capabilities, scientific R&D and infrastructure across the world;
  • Several recent highly complementary acquisitions and significant future development opportunities, given the fragmented nature of its markets and the opportunity to extend its capabilities into complementary areas;
  • High calibre management team, with Cinven and Astorg backing a highly experienced senior management team, led by Tim Robinson, CEO.

Supraj Rajagopalan, Partner at Cinven, said:

“Cinven’s investment in LGC was identified as a result of the Healthcare Sector team’s focus on the life sciences space. LGC is exposed to a wide range of diversified and fast growing end markets across the Standards and Genomics sectors and we look forward to working with the highly experienced management team to continue investing in strengthening and broadening LGC’s global footprint and portfolio of leading, high quality products.”

Francois de Mitry, Managing Partner at Astorg, added:

“We have been actively monitoring developments in the Life Sciences Tools market, with a particular focus on LGC, for over five years, and have been very impressed by LGC’s scientific capabilities and the resulting continuous organic growth. LGC represents a strong fit with Astorg’s strategy of investing in differentiated leading global B2B players headquartered in Western Europe and North America. Based on our sector work, we have already identified promising future M&A opportunities to actively work on the M&A-led growth in close cooperation with management.”

Tim Robinson, Chief Executive of LGC, commented:

“We are delighted that Astorg and Cinven have chosen to partner with LGC for the next chapter of our history. Cinven and Astorg have a strong track record of investing in and supporting the growth of global companies in the Life Sciences Tools sector. Together we will continue to invest in serving our customers and supporting the development of our employees. In the past few years, LGC has strengthened its international reach and grown significantly in its chosen markets. Astorg, Cinven and LGC’s senior management are aligned in building on this momentum with a clear strategy for growth, delivering Science for a Safer World.”

Cinven is a leading international private equity firm with a long track record of successfully investing in market-leading, growth-oriented companies serving the pharma and life sciences industry, including its investments in CeramTec, the manufacturer of high performance ceramics for application in the medical and industrial end-markets; and Sebia and Phadia – both in-vitro diagnostics companies. In addition, Cinven is currently invested in Synlab, a leading European clinical diagnostics laboratory group; and Stada, a leading global manufacturer of prescription generics and OTC products.

Astorg is a leading independent private equity firm with over €8 billion of assets under management. Astorg seeks to partner with entrepreneurial management teams to acquire market leading global companies headquartered in Western Europe and North America, working together to create value through the provision of strategic guidance, experienced governance, and adequate capital. Astorg enjoys a distinct entrepreneurial culture, a long-term shareholder perspective, and a lean decision-making body enhancing its reactivity. Though not specialised, Astorg has gathered valuable industry expertise in software, healthcare, business-to-business professional services, and technology-based industrial companies. Astorg has offices in London, Paris, Luxembourg, Frankfurt, and Milan.

Cinven and Astorg have more than 40 years history of investing in and supporting companies to drive value creation and reach their growth potential.

Financial terms of the transaction were not disclosed, with completion of the transaction subject to regulatory approval and other customary clearances.

Categories: News

Tags:

KKR Agrees Sale of LGC to Cinven and Astorg

KKR

LONDON–(BUSINESS WIRE)–Nov. 21, 2019– KKR, a leading global investment firm, announces today it has agreed to sell LGC, a global leader in the Life Science Tools sector, to a consortium led by Cinven and Astorg. Financial terms of the transaction were not disclosed.

LGC provides a comprehensive range of measurement tools, proficiency testing schemes, supply chain assurance standards and specialty genomics reagents underpinned by leading analytical and measurement science capabilities. Its scientific tools and solutions form an essential part of its customers’ quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research. The company serves customers across a number of end markets, including human healthcare, agri-food and the environment. LGC’s revenue has risen to over £448m in 2019, with organic revenue growth accelerating to 10% pa since 2016.

Tim Robinson, CEO, LGC said: “Under KKR’s ownership, LGC has further built on its mission to deliver Science for a Safer World. Our company has extended its capabilities in the areas of chemical reference standards, clinical reference materials and controls, management system standards, oligo therapeutics and next-generation sequencing. We have achieved strong organic growth aided by investment in key sites in the UK, US, Germany and China and supplemented by a range of highly complementary acquisitions. We are delighted that Cinven and Astorg have chosen to partner with LGC for the next chapter of our history. Together we will continue to invest in serving our customers and supporting the development of our employees.”

Edouard Pillot, Member and EMEA Head of Industrials at KKR, said: “LGC is a good example of KKR’s successful approach in building great companies. We identified LGC as a strong and resilient business with significant potential for further growth, and worked alongside management to support them in harnessing this potential. Tim and the LGC team have done an outstanding job over the past 4 years building LGC into a global leader. We wish them every success during their next stage of growth.”

Kugan Sathiyanandarajah, Director in the Healthcare Industry Team and Head of Europe for the Healthcare Strategic Growth Fund, said: “In 2016, we saw significant potential to build a leading global life sciences tools platform across Standards and Genomics. Since then, we are delighted to have deployed the full range of KKR’s global platform and healthcare sector expertise to support the company to grow and enter new markets, particularly in the U.S. and Asia, both organically and inorganically.”

LGC has its headquarters near London, and employs over 3,200 employees across 22 countries.

-Ends-

For more information:

About LGC

LGC is a global leader in the Life Science Tools sector, which serves customers across a number of end markets, including human healthcare, agri-food & the environment. LGC provides a comprehensive range of measurement tools, proficiency testing schemes, supply chain assurance standards and specialty genomics reagents underpinned by leading analytical and measurement science capabilities. Its scientific tools and solutions form an essential part of its customers’ quality assurance procedures and enable organisations to develop and commercialise new scientific products and advance research.

LGC’s 3,200+ employees include internationally-recognised scientists who are experts in their field. Headquartered in London, it operates out of 22 countries worldwide and is extensively accredited to quality standards such as GMP, GLP, ISO 13485, ISO 17034, ISO 17043, ISO/IEC 17025 and ISO 9001.

LGC has been home to the UK Government Chemist for more than 100 years and is the UK National Measurement Laboratory and Designated Institute for chemical and bio measurement. LGC has been privately-owned since 1996 and has diversified through internal investment and acquisition to be an international leader in its chosen markets.

For more information, please visit www.lgcgroup.com

About KKR

KKR is a leading global investment firm that manages multiple alternative asset classes, including private equity, energy, infrastructure, real estate and credit, with strategic partners that manage hedge funds. KKR aims to generate attractive investment returns for its fund investors by following a patient and disciplined investment approach, employing world-class people, and driving growth and value creation with KKR portfolio companies. KKR invests its own capital alongside the capital it manages for fund investors and provides financing solutions and investment opportunities through its capital markets business. References to KKR’s investments may include the activities of its sponsored funds. For additional information about KKR & Co. Inc. (NYSE:KKR), please visit KKR’s website at www.kkr.com and on Twitter @KKR_Co.

Source: KKR

KKR:
Alastair Elwen
Finsbury
Phone: +44 (0) 20 7251 3801
Email: alastair.elwen@finsbury.com

LGC
Guenaelle Holloway
Phone: + 44 (0) 20 8943 7563
Email: guenaelle.holloway@lgcgroup.com

Categories: News

Tags:

Combinostic raises €3.9M round led by Industrifonden and NordicNinja

Industriefonden

November 21, 2019
Combinostic computer screen of brain scan

Today we are excited to announce that we are leading a €3.9M series A funding round in Finnish health tech pioneer Combinostics. Combionstics is a cloud platform for quantitative assessment of brain images and for providing clinical decision support in neurological disorders. It is used by healthcare professionals to accelerate Alzheimer diagnoses and bring forward the start of treatment.

The company joins a family of brilliant science based startups that are improving health outcomes globally by building category-leading products. This investment represents another step for our long-term commitment to health tech innovation and scale the impact of science for the benefit of society.

“Combinostics has built a product platform from cutting-edge research that will enhance neurology departments worldwide. Their platform supports improved diagnostic accuracy and treatment choice by combining all relevant biomarkers with advanced brain image quantification, leading to improved health in neurology patients”, says Patrik Sobocki, Investment Manager at Industrifonden and responsible for the Combinostic investment.

As there are no effective treatments for neurodegenerative diseases like Alzheimer’s, early-stage diagnosis combined with symptomatic treatment and lifestyle intervention can make a drastic difference to quality of life in later years. Combinostic SaaS-solution, cNeuro, is a data driven clinical decision support tool that fits the workflow of radiologists and neurologists or other doctors specialised in memory disorders.

We believe that Combinostics have what it takes to succeed on their mission to ensure that Alzheimer and other memory disorders can be diagnosed in the future, before any symptoms appear. We are very proud to welcome Combinostic to the family.

To read more about Combinostics, please visit https://www.cneuro.com/

 

Categories: News

Tags: